

HFL-00
m37211



DEPARTMENT OF HEALTH AND HUMAN SERVICES

CFN: 1124477
Facility ID: 194589
Inspection ID #1945890006



Food and Drug Administration
Baltimore District Office
900 Madison Avenue
Baltimore, MD 21201-2199
Telephone: (410) 962-3396

April 26, 2000

WARNING LETTER

CERTIFIED MAIL
RETURN RECEIPT REQUESTED

Dr. Raymond Waters, III, Medical Director
The Radiology: MRI Institute of Maryland
9602 Martin Luther King Junior Highway
Suite F
Lanham, Maryland 20706

Dear Dr. Waters:

A representative from the State of Maryland under contract to the Food and Drug Administration (FDA) inspected your facility on April 19, 2000. This inspection revealed a serious regulatory problem involving mammography performed at your facility.

Under a United States Federal law, the Mammography Quality Standards Act (MQSA) of 1992, your facility must meet specific requirements for mammography. These requirements help protect the public health by assuring that a facility can perform quality mammography. The inspection revealed the following Level 1 finding:

- **The processing speed for the [REDACTED] was below the acceptable limit of 85 for extended film processing of mammographic films.**

The specific problem noted above appeared on your MQSA Facility Inspection Report issued to your facility at the close of the inspection. This problem is identified as a Level 1 finding because it identifies a failure to comply with a significant MQSA requirement.

Because this condition may be symptomatic of serious underlying problems that could compromise the quality of mammography performed at your facility, it represents a violation of the law that may result in FDA taking regulatory action without further notice to you.

These actions include, but are not limited to, placing your facility under a Directed Plan of Correction; charging your facility for the cost of on-site monitoring; assessing civil money penalties up to \$10,000 for each failure to substantially comply with, or each day of failure to substantially comply with, MQSA standards; suspension or revocation of your facility's FDA certificate; or obtaining a court injunction against further mammography.

It is necessary for you to act on this matter immediately. Please explain to this office in writing within fifteen (15) working days from the date you receive this letter:

- The specific steps you have taken to correct the violation noted in this letter.
- Each step your facility is taking to prevent the recurrence of similar violations.

Your response should be submitted to:

Food and Drug Administration
900 Madison Avenue
Baltimore, Maryland 21201
Attn: Nancy Rose
Compliance Officer

Finally, you should understand that there are many FDA requirements pertaining to mammography. This letter pertains only to findings of your inspection and does not necessarily address other obligations you may have under the law. You may obtain general information about all of FDA's requirements for mammography facilities by contacting the Mammography Quality Assurance Program, Food and Drug Administration, P.O. Box 6057, Columbia, MD 21045-6057 (1-800-838-7715), or through the Internet at <http://www.fda.gov>.

If you have technical questions about mammography facility requirements or about the content of this letter, please feel free to contact Elizabeth A. Laudig at (410) 962-3591, extension 159.

Sincerely,


Patrick V. McCarthy
Acting Director, Baltimore District

Dr. Raymond Waters, Medical Director

April 26, 2000

Page 3

cc: Gamal Azer, Certified MQSA Inspector
Maryland Department of the Environment
2500 Broening Highway
Baltimore, Maryland 21224

Priscilla F. Butler, M.S.
Director, Breast Imaging Accreditation Programs
Standards and Accreditation Department
American College of Radiology
1891 Preston White Drive
Reston, Virginia 22091